Group One Trading
ZNTL icon

Group One Trading’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Group One Trading’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,100
Closed -$27.1K – 8935
2025
Q4 		$27.1K Buy
20,100
+19,400
+2,771% +$28.2K ﹤0.01% 6113
2025
Q3 		$1.06K Buy
+700
New +$1.05K ﹤0.01% 8046
2025
Q2 		– Sell
-8,900
Closed -$14.2K – 8770
2025
Q1 		$14.2K Buy
8,900
+8,600
+2,867% +$18.5K ﹤0.01% 6041
2024
Q4 		$909 Hold
300
– – ﹤0.01% 6908
2024
Q3 		$1.1K Hold
300
– – ﹤0.01% 6277
2024
Q2 		$1.23K Sell
300
-1,700
-85% -$19K ﹤0.01% 6328
2024
Q1 		$31.5K Sell
2,000
-51,900
-96% -$714K ﹤0.01% 5078
2023
Q4 		$817K Buy
53,900
+49,400
+1,098% +$721K ﹤0.01% 2661
2023
Q3 		$90.3K Sell
4,500
-8,800
-66% -$223K ﹤0.01% 4547
2023
Q2 		$375K Buy
+13,300
New +$319K ﹤0.01% 3308
2023
Q1 		– Sell
-23,700
Closed -$477K – 8072
2022
Q4 		$477K Buy
+23,700
New +$510K ﹤0.01% 3087
2022
Q3 		– Sell
-600
Closed -$17K – 8364
2022
Q2 		$17K Sell
600
-9,200
-94% -$244K ﹤0.01% 6424
2022
Q1 		$452K Buy
9,800
+4,500
+85% +$243K ﹤0.01% 3918
2021
Q4 		$446K Buy
5,300
+4,300
+430% +$333K ﹤0.01% 4264
2021
Q3 		$67K Sell
1,000
-4,100
-80% -$237K ﹤0.01% 6305
2021
Q2 		$271K Buy
+5,100
New +$273K ﹤0.01% 4893

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Group One Trading's ZNTL Position: Q1 2026 in Review

Group One Trading opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 1,460 shares worth $3.42K. The stake represents ﹤0.01% of the portfolio and ranks #6869 among its holdings. This is a return to the name: Group One Trading previously reported a position in ZNTL as recently as Q2 2025.

Group One Trading first reported a position in ZNTL in Q2 2022 and has held it in 7 quarters since. The position peaked at $433K in Q4 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Group One Trading held 1,460 shares of Zentalis Pharmaceuticals worth $3.42K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new Group One Trading position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6869 holding.
  • Group One Trading first reported a position in Zentalis Pharmaceuticals in Q2 2022 and has held it in 7 quarters since.
  • Group One Trading's Zentalis Pharmaceuticals position peaked at $433K in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.